Tag results:
breast cancer cells
Mammary Cell News
The Targetable Nanoparticle BAF312@cRGD-CaP-NP Represses Tumor Growth and Angiogenesis by Downregulating the S1PR1/P-STAT3/VEGFA Axis in Triple-Negative Breast Cancer
[Journal of Nanobiotechnology] Researchers prepared shell-core structure nanoparticles which inhibited tumor growth and angiogenesis in vitro and in MDA-MB-231 tumor-bearing mice via downregulating the sphingosine 1 phosphate receptor 1/phosphorylated signal transducer and activator of transcription 3/vascular endothelial growth factor A axis.
Mammary Cell News
Disruption of STAT5A and NMI Signaling Axis Leads to ISG20-Driven Metastatic Mammary Tumors
[Oncogenesis] Researchers investigated the relevance of the interactions between N-Myc and STAT Interactor protein (NMI) and various STATs to normal mammary development and cancer.
Mammary Cell News
Cannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program
[Cannabics Pharmaceuticals, Inc. (PR Newswire, Inc.)] Cannabics Pharmaceuticals, Inc. announced the launching of a new research program for the development of a breast cancer antitumor targeting medicine following the successful completion of a series of preclinical experiments.
Cancer Stem Cell News
ETV4 Promotes Breast Cancer Cell Stemness by Activating Glycolysis and CXCR4-Mediated Sonic Hedgehog Signaling
[Cell Death Discovery] Regulation of cancer cell metabolism rewiring and stemness is not completely understood. Scientists reported that ETV4 is a key transcription factor in regulating glycolytic gene expression.
Cancer Stem Cell News
Syndecan-1 Depletion Has a Differential Impact on Hyaluronic Acid Metabolism and Tumor Cell Behavior in Luminal and Triple-Negative Breast Cancer Cells
[International Journal of Molecular Sciences] Investigators studied the effect of syndecan-1 siRNA depletion and hyaluronic acid treatment on hallmark processes of cancer in breast cancer cell lines of different levels of aggressiveness.
Human Immunology News
Low-Dose CDK4/6 Inhibitors Induce Presentation of Pathway Specific MHC Ligands as Potential Targets for Cancer Immunotherapy
[Oncoimmunology] Researchers investigated the effects of CDK4/6i, abemaciclib and palbociclib, on the immunopeptidome at nontoxic levels in breast cancer cell lines using biochemical identification of HLA ligands followed by network analyses.